Open Orphan - Contract signed with Carna Bioscience
ORPH Mon, 18 Nov 2019, 01:25pm GMT
Cathal Friel, Chief Executive of Open Orphan is pleased to announce the signing of a contract with Carna Bioscience for a First In Human Clinical pharmacology trial. The contract is expected to deliver significant revenue for the Company over the next twelve months.
Cathal Friel
CEO
Yamin 'Mo' Khan, Chief Executive Officer
Fri, 5 Aug 2022, 7:05am BST
Jeremy Skillington, CEO, Poolbeg Pharma
Mon, 18 Jul 2022, 7:00am BST
Dr. Andrew Catchpole, Chief Scientist
Tue, 14 Jun 2022, 7:05am BST
Yamin 'Mo' Khan, Chief Executive Officer
Tue, 7 Jun 2022, 7:05am BST
Yamin 'Mo' Khan, Chief Executive Officer
Fri, 6 May 2022, 7:05am BST
Yamin 'Mo' Khan, Chief Executive Officer
Mon, 28 Mar 2022, 9:00am BST
Robin Rogiers, Director Clinical Delivery & Innovation, hVIVO
Tue, 8 Mar 2022, 9:00am GMT
Cathal Friel, Executive Chairman
Thu, 24 Feb 2022, 7:00am GMT
Adrian Wildfire, Director of Scientific & Business Strategy, hVIVO
Mon, 14 Feb 2022, 10:30am GMT
Dr. Andrew Catchpole, Chief Scientist
Wed, 2 Feb 2022, 10:00am GMT
Cathal Friel, Executive Chairman
Wed, 2 Feb 2022, 10:00am GMT
Adrian Wildfire, Director of Scientific & Business Strategy, hVIVO
Thu, 20 Jan 2022, 4:30pm GMT
Cathal Friel, Executive Chairman
Thu, 20 Jan 2022, 1:40pm GMT
Cathal Friel, Executive Chairman
Fri, 10 Dec 2021, 9:06am GMT
Cathal Friel, Executive Chairman
Mon, 20 Sep 2021, 8:00am BST
Cathal Friel, Executive Chairman
Tue, 24 Aug 2021, 7:15am BST
Cathal Friel, Executive Chairman
Wed, 14 Jul 2021, 12:00pm BST
Management Team, Open Orphan
Mon, 14 Dec 2020, 7:00am GMT
